USD
GBP
CNY
EUR
INR
JPY
MYR
ZAR
KRW
THB
Global Biologics Contract Development and Manufacturing Organizations Growth Opportunities
Global Biologics Contract Development and Manufacturing Organizations Growth Opportunities Updated Research Available
Asset Co-Development with Clinical-stage Biopharmaceutical Companies and Disruptive Technologies Present Future Growth Potential
17-Jun-2021
North America
Description
This study presents Frost & Sullivan’s overall market and segment-wise revenue forecasts of the global biologics contract development and manufacturing organizations (bio-CDMO) market. It also highlights key growth opportunities for bio-CDMO market participants based on the main evolution in their business models and strategic approaches, as well as those of the pharmaceutical sponsors. The study segments the market by product (drug substance and drug product), cell line (mammalian, microbial, and viral vectors and other modalities) and service (clinical and commercial) types. The market forecasts in this report are for 2020–2026. They capture key market developments, such as capacity expansions, mergers, acquisitions, and expanding services offerings set to impact the overall bio-CDMO market growth.
Other discussions on the global bio-CDMO market include:
• Impact of strategic imperatives on the industry
• Growth drivers and restraints
• Comprehensive insights on its competitive landscape
• Revenue share estimates of top market participants
• A strategic analysis of market developments regarding services offerings and business models
• Growth opportunities centered on single-use technology in the development and manufacturing of personalized medicine, COVID-19 vaccine scale-up partnerships, assets co-development with small and midsize pharma companies, and opportunities in China’s domestic biopharma market
Author: Deepak Jayakumar
RESEARCH: INFOGRAPHIC
This infographic presents a brief overview of the research, and highlights the key topics discussed in it.Click image to view it in full size
Table of Contents
Why is it Increasingly Difficult to Grow?
The Strategic Imperative 8™
The Impact of the Top Three Strategic Imperatives on the Biologics Contract Development and Manufacturing Organizations Industry
Growth Opportunities Fuel the Growth Pipeline Engine™
Bio-CDMO Market Scope of Analysis
Bio-CDMO Market Segmentation by Product Type
Bio-CDMO Market Segmentation by Cell Line Type
Bio-CDMO Market Segmentation by Service Type
Key Competitors for the Bio-CDMO Market
Key Growth Metrics for the Global Bio-CDMO Market
Growth Drivers for Bio-CDMO Market
Growth Restraints for the Bio-CDMO Market
Forecast Framework, Bio-CDMO Market
Forecast Methodology, Bio-CDMO Market
Forecast Assumptions and Considerations, Bio-CDMO Market
Revenue Forecast, Bio-CDMO Market
Revenue Forecast Analysis, Bio-CDMO Market
Revenue Forecast by Product Type, Bio-CDMO Market
Revenue Forecast Analysis by Product Type, Bio-CDMO Market
Revenue Forecast by Cell Line Type, Bio-CDMO Market
Revenue Forecast Analysis by Cell Line Type, Bio-CDMO Market
Revenue Split by Service Type, Bio-CDMO Market
Revenue Forecast Analysis by Service Type, Bio-CDMO Market
Regional Analysis, Bio-CDMO Market
Competitive Environment, Bio-CDMO Market
Revenue Share, Bio-CDMO Market
Revenue Share Analysis, Bio-CDMO Market
Top Bio-CDMOs Edging Closer to a Comprehensive One-Stop-Shop Service Offering
Growth Avenues, Bio-CDMO Industry
Transitions in Bio-CDMO Business Models
Growth Opportunity Analysis Mapping, Bio-CDMO Market
Growth Opportunity 1—Adoption of Single-Use Technology for Cell and Gene Therapy Manufacturing
Growth Opportunity 1—Adoption of Single-Use Technology for Cell and Gene Therapy Manufacturing (continued)
Growth Opportunity 2—Capacity-Building Partnerships for COVID-19 Vaccine Manufacturing
Growth Opportunity 2—Capacity-Building Partnerships for COVID-19 Vaccine Manufacturing(continued)
Bio-CDMO Milestones for COVID-19 Vaccine Manufacturing
Growth Opportunity 3—Co-Developing Antibody Therapies with Clinical-stage Biopharma Companies
Growth Opportunity 3—Co-Developing Antibody Therapies with Clinical-stage Biopharma Companies (continued)
Growth Opportunity 4—Addressing Capacity Scale-up Needs of China’s Domestic Biopharma Market
Growth Opportunity 4—Addressing Capacity Scale-up Needs of China’s Domestic Biopharma Market (continued)
China’s Biologics Pipeline
Your Next Steps
Why Frost, Why Now?
List of Exhibits
Legal Disclaimer
Popular Topics
| No Index | No |
|---|---|
| Podcast | No |
| Author | Deepak Jayakumar |
| Industries | Healthcare |
| WIP Number | MG0C-01-00-00-00 |
| Is Prebook | No |
| GPS Codes | 9600-B1,9571-B1,99C1-B1,9568-B1,9611-B1 |
